# SAB Biotherapeutics, Inc.: financial statements, quarterly

SABS · Nasdaq · CIK 1833214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sabs.md) · [Financials](/companies/sabs/financials.md) · [Filings](/companies/sabs/filings.md) · [Insiders](/companies/sabs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sabs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.3](/filings/0000950170-24-122443.md) | [0.3 d](/filings/0000950170-25-046994.md) | [0.9](/filings/0000950170-25-067554.md) | [0.3](/filings/0000950170-25-104566.md) | [0.0 d](/filings/0001193125-25-280572.md) | [0.1 d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [4.0](/filings/0000950170-24-122443.md) | [4.3 d](/filings/0000950170-25-046994.md) | [8.1](/filings/0000950170-25-067554.md) | [6.8](/filings/0000950170-25-104566.md) | [7.8](/filings/0001193125-25-280572.md) | [7.7 d](/filings/0001833214-26-000003.md) | [7.7](/filings/0001193125-26-218195.md) | [7.0](/filings/0001193125-26-336783.md) | [9.0](/filings/0001193125-25-280572.md) | [10.7 d](/filings/0001833214-26-000003.md) | [13.4](/filings/0001193125-26-218195.md) | [16.2](/filings/0001193125-26-336783.md) |
| Operating income | $m | [(5.3)](/filings/0000950170-24-122443.md) | [(18.9) d](/filings/0000950170-25-046994.md) | [(11.4)](/filings/0000950170-25-067554.md) | [(10.2)](/filings/0000950170-25-104566.md) | [(11.3)](/filings/0001193125-25-280572.md) | [(10.0) d](/filings/0001833214-26-000003.md) | [(10.8)](/filings/0001193125-26-218195.md) | [(9.7)](/filings/0001193125-26-336783.md) | [(12.7)](/filings/0001193125-25-280572.md) | [(15.8) d](/filings/0001833214-26-000003.md) | [(20.0)](/filings/0001193125-26-218195.md) | [(23.4)](/filings/0001193125-26-336783.md) |
| Interest expense | $m | [0.1](/filings/0000950170-23-063076.md) | [0.1 d](/filings/0000950170-24-038219.md) | [0.1](/filings/0000950170-24-062367.md) | [0.1](/filings/0000950170-24-094084.md) | [0.1](/filings/0001193125-25-280572.md) | [0.1 d](/filings/0001833214-26-000003.md) | [0.1](/filings/0001193125-26-218195.md) | [0.1](/filings/0001193125-26-336783.md) | [0.0](/filings/0001193125-25-280572.md) | [0.1 d](/filings/0001833214-26-000003.md) | [0.1](/filings/0001193125-26-218195.md) | [0.1](/filings/0001193125-26-336783.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(5.1)](/filings/0000950170-24-122443.md) | [(22.9) d](/filings/0000950170-25-046994.md) | [(5.0)](/filings/0001193125-25-280572.md) | [(7.3)](/filings/0001193125-25-280572.md) | [(10.3)](/filings/0001193125-25-280572.md) | [(11.4) d](/filings/0001833214-26-000003.md) | [(5.2)](/filings/0001193125-26-336783.md) | [(10.1)](/filings/0001193125-26-336783.md) | [45.4](/filings/0001193125-25-280572.md) | [(16.9) d](/filings/0001833214-26-000003.md) | [(18.9)](/filings/0001193125-26-336783.md) | [(22.5)](/filings/0001193125-26-336783.md) |
| Diluted EPS | $ per share | [(0.97)](/filings/0000950170-24-122443.md) | not reported | [(0.54)](/filings/0000950170-25-067554.md) | [(0.79)](/filings/0000950170-25-104566.md) | [(1.12)](/filings/0001193125-25-280572.md) | not reported | [(0.56)](/filings/0001193125-26-218195.md) | [(1.09)](/filings/0001193125-26-336783.md) | [(0.21)](/filings/0001193125-25-280572.md) | not reported | [(0.35)](/filings/0001193125-26-218195.md) | [(0.28)](/filings/0001193125-26-336783.md) |
| Basic EPS | $ per share | [(0.97)](/filings/0000950170-24-122443.md) | not reported | [(0.54)](/filings/0000950170-25-067554.md) | [(0.79)](/filings/0000950170-25-104566.md) | [(1.12)](/filings/0001193125-25-280572.md) | not reported | [(0.56)](/filings/0001193125-26-218195.md) | [(1.09)](/filings/0001193125-26-336783.md) | [0.50](/filings/0001193125-25-280572.md) | not reported | [(0.35)](/filings/0001193125-26-218195.md) | [(0.28)](/filings/0001193125-26-336783.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.4](/filings/0000950170-23-063076.md) | [56.6](/filings/0000950170-25-046994.md) | [14.0](/filings/0000950170-24-062367.md) | [17.2](/filings/0000950170-24-094084.md) | [9.2](/filings/0000950170-24-122443.md) | [8.9](/filings/0001833214-26-000003.md) | [5.6](/filings/0000950170-25-067554.md) | [3.7](/filings/0000950170-25-104566.md) | [29.4](/filings/0001193125-25-280572.md) | [10.5](/filings/0001193125-26-336783.md) | [20.5](/filings/0001193125-26-218195.md) | [8.3](/filings/0001193125-26-336783.md) |
| Current assets | $m | [3.1](/filings/0000950170-23-063076.md) | [58.9](/filings/0000950170-25-046994.md) | [47.0](/filings/0000950170-24-062367.md) | [39.6](/filings/0000950170-24-094084.md) | [32.5](/filings/0000950170-24-122443.md) | [23.8](/filings/0001833214-26-000003.md) | [16.3](/filings/0000950170-25-067554.md) | [9.3](/filings/0000950170-25-104566.md) | [113](/filings/0001193125-25-280572.md) | [101](/filings/0001193125-26-336783.md) | [113](/filings/0001193125-26-218195.md) | [108](/filings/0001193125-26-336783.md) |
| Total assets | $m | [28.3](/filings/0000950170-23-063076.md) | [83.9](/filings/0000950170-25-046994.md) | [71.4](/filings/0000950170-24-062367.md) | [61.9](/filings/0000950170-24-094084.md) | [53.8](/filings/0000950170-24-122443.md) | [44.2](/filings/0001833214-26-000003.md) | [38.1](/filings/0000950170-25-067554.md) | [30.1](/filings/0000950170-25-104566.md) | [183](/filings/0001193125-25-280572.md) | [173](/filings/0001193125-26-336783.md) | [248](/filings/0001193125-26-218195.md) | [238](/filings/0001193125-26-336783.md) |
| Current liabilities | $m | [9.2](/filings/0000950170-23-063076.md) | [10.8](/filings/0000950170-25-046994.md) | [8.3](/filings/0000950170-24-062367.md) | [7.6](/filings/0000950170-24-094084.md) | [8.8](/filings/0000950170-24-122443.md) | [8.0](/filings/0001833214-26-000003.md) | [9.7](/filings/0000950170-25-067554.md) | [10.7](/filings/0000950170-25-104566.md) | [10.8](/filings/0001193125-25-280572.md) | [10.7](/filings/0001193125-26-336783.md) | [9.9](/filings/0001193125-26-218195.md) | [11.7](/filings/0001193125-26-336783.md) |
| Total liabilities | $m | [13.1](/filings/0000950170-23-063076.md) | [26.6](/filings/0000950170-25-046994.md) | [18.5](/filings/0000950170-24-062367.md) | [15.8](/filings/0000950170-24-094084.md) | [16.9](/filings/0000950170-24-122443.md) | [18.2](/filings/0001833214-26-000003.md) | [16.7](/filings/0000950170-25-067554.md) | [18.1](/filings/0000950170-25-104566.md) | [18.4](/filings/0001193125-25-280572.md) | [21.3](/filings/0001193125-26-336783.md) | [21.2](/filings/0001193125-26-218195.md) | [23.4](/filings/0001193125-26-336783.md) |
| Shareholders' equity | $m | [15.3](/filings/0000950170-24-122443.md) | [57.3](/filings/0001833214-26-000003.md) | [52.8](/filings/0001193125-25-280572.md) | [46.1](/filings/0001193125-25-280572.md) | [36.9](/filings/0001193125-25-280572.md) | [26.0](/filings/0001193125-26-336783.md) | [21.4](/filings/0001193125-26-336783.md) | [12.0](/filings/0001193125-26-336783.md) | [165](/filings/0001193125-25-280572.md) | [151](/filings/0001193125-26-336783.md) | [227](/filings/0001193125-26-336783.md) | [215](/filings/0001193125-26-336783.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.2) d](/filings/0000950170-24-122443.md) | [(13.4) d](/filings/0000950170-25-046994.md) | [(10.8)](/filings/0000950170-25-067554.md) | [(7.7) d](/filings/0000950170-25-104566.md) | [(6.3) d](/filings/0001193125-25-280572.md) | [(9.5) d](/filings/0001833214-26-000003.md) | [(7.8)](/filings/0001193125-26-218195.md) | [(7.2) d](/filings/0001193125-26-336783.md) | [(13.0) d](/filings/0001193125-25-280572.md) | [(16.8) d](/filings/0001833214-26-000003.md) | [(14.3)](/filings/0001193125-26-218195.md) | [(9.8) d](/filings/0001193125-26-336783.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-122443.md) | [0.1 d](/filings/0000950170-25-046994.md) | [0.1](/filings/0000950170-25-067554.md) | [0.1 d](/filings/0000950170-25-104566.md) | [0.1 d](/filings/0001193125-25-280572.md) | [0.1 d](/filings/0001833214-26-000003.md) | not reported | not reported | not reported | not reported | [1.0](/filings/0001193125-26-218195.md) | [1.6 d](/filings/0001193125-26-336783.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [43.0](/filings/0000950170-23-063076.md) | [5.0](/filings/0000950170-24-062367.md) | [5.0](/filings/0000950170-24-094084.md) | [5.2](/filings/0000950170-24-122443.md) | [9.2](/filings/0000950170-25-067554.md) | [9.3](/filings/0000950170-25-104566.md) | [9.3](/filings/0001193125-25-280572.md) | [9.3](/filings/0001193125-26-218195.md) | [9.3](/filings/0001193125-26-336783.md) | [77.9](/filings/0001193125-25-280572.md) | [53.6](/filings/0001193125-26-218195.md) | [79.8](/filings/0001193125-26-336783.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 90,986,368 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336783.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.